S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
As Musk is learning, content moderation is a messy job
Intel is a Sleeping Giant Ready to Awaken
🚨 [Strong Buy Alert] Is this laser stock in your portfolio? (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
Reformers take 6 of 14 UAW board seats, could win majority
NYSE:CTLT

Catalent - CTLT Stock Forecast, Price & News

$52.25
+0.02 (+0.04%)
(As of 12/2/2022 09:00 PM ET)
Add
Compare
Today's Range
$51.19
â–¼
$53.06
50-Day Range
$41.39
â–¼
$81.00
52-Week Range
$40.69
â–¼
$130.97
Volume
4.21 million shs
Average Volume
1.63 million shs
Market Capitalization
$9.40 billion
P/E Ratio
22.33
Dividend Yield
N/A
Price Target
$92.80

Catalent MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
77.6% Upside
$92.80 Price Target
Short Interest
Healthy
1.99% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.20mentions of Catalent in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$233,387 Sold Last Quarter
Proj. Earnings Growth
15.38%
From $3.12 to $3.60 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.25 out of 5 stars

Medical Sector

3rd out of 1,033 stocks

Pharmaceutical Preparations Industry

1st out of 502 stocks

See Top Rated MarketRank™ Stocks Here
CTLT stock logo

About Catalent (NYSE:CTLT) Stock

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Stock News Headlines

November 14, 2022 | marketbeat.com
After a $100 Haircut, is Catalent an Oversold Pharma Play?
With the macro backdrop weakening for Catalent’s pharmaceutical and biotech customers, fundamental concerns could outweigh what the charts suggest.
November 30, 2022 | americanbankingnews.com
Catalent (NYSE:CTLT) Trading 6% Higher
November 27, 2022 | finance.yahoo.com
Should You Add Catalent (CTLT) to Your Portfolio for the Long-Term?
November 16, 2022 | finance.yahoo.com
Bear Of The Day: Catalent (CTLT)
November 15, 2022 | finance.yahoo.com
Here’s Why Catalent (CTLT) Underperformed in the Third Quarter
November 11, 2022 | finance.yahoo.com
ClearBridge Investments’ Worst Q3 Performer: Catalent (CTLT)
November 4, 2022 | finance.yahoo.com
Why Shares of Catalent Fell 36% This Week
November 3, 2022 | finance.yahoo.com
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
November 1, 2022 | finance.yahoo.com
Catalent (CTLT) Q1 Earnings Lag Estimates, FY23 View Cut
November 1, 2022 | investorplace.com
Why Is Catalent (CTLT) Stock Down 24% Today?
November 1, 2022 | finance.yahoo.com
Catalent, Inc. Reports First Quarter Fiscal 2023 Results
November 1, 2022 | finance.yahoo.com
Catalent (CTLT) Q1 Earnings and Revenues Miss Estimates
October 26, 2022 | finance.yahoo.com
Catalent (CTLT) to Report Q1 Earnings: What's in the Cards?
October 25, 2022 | finance.yahoo.com
Analysts Estimate Catalent (CTLT) to Report a Decline in Earnings: What to Look Out for
October 24, 2022 | bizjournals.com
Catalent plans $12M expansion of biopharma facility in south Kansas City
October 20, 2022 | finance.yahoo.com
Catalent Expands Biologics Analytical Capabilities with New Laboratories at Center of Excellence in Kansas City, Missouri - Yahoo Finance
October 19, 2022 | seekingalpha.com
Catalent Stock: Charting A Post-Covid Future (NYSE:CTLT) - Seeking Alpha
October 17, 2022 | finance.yahoo.com
Catalent, Inc. Announces First Quarter Fiscal Year 2023 Earnings Conference Webcast
October 17, 2022 | finance.yahoo.com
Catalent (NYSE:CTLT) sheds 6.4% this week, as yearly returns fall more in line with earnings growth
October 13, 2022 | finance.yahoo.com
Clinical Trials Supply & Logistics Market to Reach $6.23 Billion by 2030 at a CAGR of 7.4% - Yahoo Finance
October 12, 2022 | cnbc.com
Jim Cramer goes over the best and worst Q3 performers in the S&P 500 - CNBC
October 11, 2022 | businesswire.com
High Potency API Contract Manufacturing Market Report 2022: Featuring Piramal Pharma Solutions, Lonza, Pfizer, Catalent & More - ResearchAndMarkets.com - Business Wire
October 6, 2022 | benzinga.com
7 Analysts Have This to Say About Catalent - Catalent (NYSE:CTLT) - Benzinga
October 4, 2022 | businesswire.com
Clinical Trials Supply & Logistics Market Report 2022: Technological Advancements in Supply Chain to Drive Growth - ResearchAndMarkets.com - Business Wire
September 29, 2022 | nasdaq.com
The total return for Catalent (NYSE:CTLT) investors has risen faster than earnings growth over the last five years
See More Headlines
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Company Calendar

Last Earnings
11/01/2022
Today
12/05/2022
Next Earnings (Estimated)
2/07/2023
Fiscal Year End
6/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:CTLT
CUSIP
N/A
CIK
1596783
Web
www.catalent.com
Phone
(732) 537-6200
Fax
732-537-6480
Employees
19,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$92.80
High Stock Price Forecast
$145.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
+77.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$2.34
Trailing P/E Ratio
22.33
Forward P/E Ratio
16.75
P/E Growth
2.31
Net Income
$503 million
Net Margins
8.83%
Pretax Margin
10.47%
Return on Equity
12.55%
Return on Assets
5.66%

Debt

Debt-to-Equity Ratio
0.87
Current Ratio
2.86
Quick Ratio
2.08

Sales & Book Value

Annual Sales
$4.83 billion
Price / Sales
1.95
Cash Flow
$5.82 per share
Price / Cash Flow
8.97
Book Value
$26.12 per share
Price / Book
2.00

Miscellaneous

Outstanding Shares
179,964,000
Free Float
178,920,000
Market Cap
$9.40 billion
Optionable
Optionable
Beta
1.23

Key Executives

  • Mr. John R. ChiminskiMr. John R. Chiminski (Age 58)
    Exec. Chair of the Board
    Comp: $3.11M
  • Mr. Alessandro MaselliMr. Alessandro Maselli (Age 50)
    CEO & Director
    Comp: $1.53M
  • Mr. Thomas P. CastellanoMr. Thomas P. Castellano (Age 42)
    Sr. VP & CFO
    Comp: $1.07M
  • Mr. Steven L. Fasman Esq.Mr. Steven L. Fasman Esq. (Age 59)
    Exec. VP, Corp. Sec. & Chief Admin. Officer
    Comp: $1.3M
  • Dr. Aristippos Gennadios Ph.D.Dr. Aristippos Gennadios Ph.D. (Age 56)
    Group Pres of Pharma & Consumer Health Segment
    Comp: $1.13M
  • Mr. Ricky Hopson (Age 46)
    Pres & Division Head for Clinical Devel. and Supply
  • Ms. Karen Murphy Santiago (Age 51)
    VP & Chief Accounting Office
  • Mr. Julien Meissonnier
    VP & Chief Scientific Officer
  • Mr. Charles Lickfold (Age 48)
    Sr. VP & Chief Information Officer
  • Mr. Paul Surdez
    VP of Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CTLT Stock - Frequently Asked Questions

Should I buy or sell Catalent stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CTLT shares.
View CTLT analyst ratings or view top-rated stocks.

What is Catalent's stock price forecast for 2023?

8 Wall Street analysts have issued 12 month target prices for Catalent's stock. Their CTLT share price forecasts range from $60.00 to $145.00. On average, they predict the company's stock price to reach $92.80 in the next year. This suggests a possible upside of 77.6% from the stock's current price.
View analysts price targets for CTLT or view top-rated stocks among Wall Street analysts.

How have CTLT shares performed in 2022?

Catalent's stock was trading at $128.03 at the start of the year. Since then, CTLT shares have decreased by 59.2% and is now trading at $52.25.
View the best growth stocks for 2022 here.

Are investors shorting Catalent?

Catalent saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 3,580,000 shares, a decline of 11.8% from the October 31st total of 4,060,000 shares. Based on an average trading volume of 2,390,000 shares, the days-to-cover ratio is currently 1.5 days.
View Catalent's Short Interest.

When is Catalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our CTLT earnings forecast.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) announced its earnings results on Tuesday, November, 1st. The company reported $0.25 EPS for the quarter, missing the consensus estimate of $0.49 by $0.24. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.06 billion. Catalent had a trailing twelve-month return on equity of 12.55% and a net margin of 8.83%.
Read the conference call transcript.

What guidance has Catalent issued on next quarter's earnings?

Catalent issued an update on its FY 2023 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of $3.13-$3.54 for the period, compared to the consensus EPS estimate of $3.76. The company issued revenue guidance of $4.63 billion-$4.88 billion, compared to the consensus revenue estimate of $5.08 billion.

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

Who are Catalent's major shareholders?

Catalent's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.68%), BlackRock Inc. (8.94%), State Street Corp (3.96%), Veritas Asset Management LLP (3.87%), Artisan Partners Limited Partnership (3.26%) and Price T Rowe Associates Inc. MD (1.07%). Insiders that own company stock include Alessandro Maselli, Aristippos Gennadios, Associates LP Ta, Gregory T Lucier, Gregory T Lucier, John R Chiminski, John R Chiminski, Jonathan Arnold, Karen Flynn, Kay A Schmidt, Kay A Schmidt, Mario Gargiulo, Michael A Riley, Michael J Grippo, Michael J Grippo, Peter Zippelius, Ricardo Pravda, Ricci S Whitlow, Ricci S Whitlow, Ricky Hopson, Scott Gunther, Steven L Fasman, Steven L Fasman, Thomas P Castellano, Thomas W Hawkeswood and Wetteny Joseph.
View institutional ownership trends.

How do I buy shares of Catalent?

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $52.25.

How much money does Catalent make?

Catalent (NYSE:CTLT) has a market capitalization of $9.40 billion and generates $4.83 billion in revenue each year. The company earns $503 million in net income (profit) each year or $2.34 on an earnings per share basis.

How many employees does Catalent have?

The company employs 19,000 workers across the globe.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480.

This page (NYSE:CTLT) was last updated on 12/5/2022 by MarketBeat.com Staff